Value | S33005 | Venlafaxine | Clomipramine | Citalopram | Reboxetine | |
---|---|---|---|---|---|---|
DRN | ID50 | 0.019 | 0.11 | 0.07 | 0.07 | |
(95% CL) | (0.014–0.024) | (0.09–0.13) | (0.06–0.08) | (0.06–0.08) | ||
LC | ID50 | 0.25 | 1.0 | 6.0 | 0.11 | |
(95% CL) | (0.22–0.29) | (0.9 –1.2) | (4.5 –8.6) | (0.10–0.13) | ||
PCA:FCX | ID50 | 0.18 | 1.0 | 1.2 | 0.22 | >10 |
(95% CL) | (0.11–0.27) | (0.7 –1.4) | (0.7 –1.9) | (0.13–2.7) | ||
PCA:Hippocampus | ID50 | 0.35 | 2.5 | 3.3 | 0.41 | >10 |
(95% CL) | (0.17–0.66) | (1.7 –3.6) | (1.7 –6.3) | (0.32–0.53) | ||
FCX:5-HT | MED | 0.04 | 0.63 | 2.5 | 0.63 | >40.0 |
FCX:NE | MED | 0.16 | 0.63 | 2.5 | 10 | 0.04 |
FCX:DA | MED | 0.16 | 2.5 | 2.5 | 40 | 0.04 |
DRN and LC, inhibition of firing rate of dorsal raphe nucleus-serotonergic and locus ceruleus-adrenergic neurones, respectively; PCA, inhibition of depletion by parachloroamphetamine of serotonin levels in frontal cortex (FCX) and hippocampus; for FCX: 5-HT, NE, and DA, elevation of dialysate levels of serotonin, norepinephrine, and dopamine, respectively, in frontal cortex; MED, minimal effective dose. Doses are in mg/kg, s.c. or i.v. (DRN and LC, firing rate).